News & Announcements
-
2025 TaMADOR Meeting at the NIH
March 4, 2025The TaMADOR consortium held a symposium at the National Institutes of Health on March 4, 2025: Biomarkers and Mass Spectrometry–Based Assays in Type 1 Diabetes Clinical Research.
-
New Publications Page
April 25, 2024We have launched a new page listing the publications from the four grants that have supported TaMADOR:
-
Register Now for the 2024 TaMADOR Symposium
March 28, 2024Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR)
-
UW and PNNL Funded to Develop Assays for Type 1 Diabetes
September 6, 2023The TaMADOR program was funded with cooperative agreements between the NIDDK and consortium institutions a few years ago, and will now continue with emphasis on the development of assays of importance in type 1 diabetes clinical research.
-
Multiplexed Quantification of Insulin and C-peptide by LC-MS/MS Without Antibodies
September 6, 2023The Hoofnagle lab has developed an LC-MS/MS assay to measure insulin and C-peptide without the use of antibodies.
-
2022 TaMADOR Meeting in Bethesda
October 27, 2022The TaMADOR consortium met in Bethesda, MD on December 1, 2022 for a symposium on advances in multiplex quantification of protein/peptide hormones and biomarkers involved in obesity and diabetes.
-
MSACL Workshop on the Development, Validation, and Implementation of Obesity and Diabetes Assays
June 2, 2021The TaMADOR consortium held a virtual workshop on June 3, 2021 at the MSACL (Mass Spectrometry: Applications to the Clinical Lab) conference.
-
Announcing TaMADOR: A Collaborative Working Group for Targeted Mass Spectrometry Assays
May 8, 2020Two NIDDK programs, one focused on Type 1 Diabetes and one focused on Obesity, are working together to develop and share quantitative protein assays.